Literature DB >> 26142665

Current studies on human papillomavirus in Saudi Arabia.

Fatimah Saeed Alhamlan1, Ahmed A Al-Qahtani, Mohammed N Al-Ahdal.   

Abstract

Human papillomavirus (HPV) infection is a significant etiological factor and an important prognosticator in cervical cancer. Indeed, researchers worldwide have confirmed these roles for high-risk HVPs in over 70% of cervical cancer cases. According to the World Health Organization, approximately 561,200 new cancer cases (5.2% of all new cancers) are attributed to HPV infection. Over 120 types of HPV are classified further as either low-risk HPV (LR-HPV) or high-risk HPV (HR-HPV) based on their oncological potential of transforming cells. The LR-HPV types cause benign hyperproliferative lesions (i.e. genital warts) while the HR-HPV types are strongly associated with premalignant and malignant cervical lesions. Data on the prevalence of HPV, survival of infected patients, and mortality rate are scarce in Saudi Arabia. The unsubstantiated assumption of a low prevalence of HPV in Saudi Arabia has contributed to limiting HPV research in this conservative country. Therefore, the goal of this review is to shed light on the current HPV research being conducted and the prevalence of HPV in Saudi Arabia.

Entities:  

Mesh:

Year:  2015        PMID: 26142665     DOI: 10.3855/jidc.6538

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  10 in total

1.  Human papillomavirus and its vaccination: Knowledge and attitudes among female university students in Saudi Arabia.

Authors:  Tahani Altamimi
Journal:  J Family Med Prim Care       Date:  2020-04-30

2.  The Diagnosis of Cervical Dysplasia in a University Hospital Using Pap Smear and Colposcopy in the Western Region of Saudi Arabia: A Correlational Study.

Authors:  Wejdan O Baamer; Nisreen Anfinan; Maram Sait; Omar Baghlaf; Nashwa AlDardir; Asem Sebghatallah; Bayan Alkhalili; Mohammed Sulaimani; Rahaf Alghamdi; Khalid H Sait
Journal:  Cureus       Date:  2022-03-17

3.  Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.

Authors:  Ghazi A Alsbeih; Najla M Al-Harbi; Sara S Bin Judia; Hatim A Khoja; Mohamed M Shoukri; Asma M Tulbah
Journal:  Cancer       Date:  2017-04-10       Impact factor: 6.860

4.  Genetic diversity and phylogenetic analysis of HPV 16 & 18 variants isolated from cervical specimens of women in Saudi Arabia.

Authors:  Khalid Sait; Rola Turki; Adel Mohammed Abuzenadah; Osama H Jiffiri; Abdulbaset Bohmaidah; Sayed Sartaj Sohrab
Journal:  Saudi J Biol Sci       Date:  2018-05-03       Impact factor: 4.219

5.  Condyloma accuminatum of the male urethra: A case report.

Authors:  Abdelrazak Meliti; Abdulrahman Hawari; Haneen Al-Maghrabi; Ghadeer Mokhtar
Journal:  SAGE Open Med Case Rep       Date:  2020-02-21

6.  Prevalence of human papillomavirus in Jeddah, Saudi Arabia.

Authors:  Manar Mousa; Sawsan S Al-Amri; Afnan A Degnah; Ahmed M Tolah; Hanin H Abduljabbar; Ayman M Oraif; Hassan S Abduljabbar; Ahmed A Mirza; Esam I Azhar; Anwar M Hashem
Journal:  Ann Saudi Med       Date:  2019-12-05       Impact factor: 1.526

7.  Knowledge, attitudes and perceptions regarding human papillomavirus among university students in Hail, Saudi Arabia.

Authors:  Farhan Alshammari; Kashif Ullah Khan
Journal:  PeerJ       Date:  2022-03-23       Impact factor: 2.984

8.  Exploring the Causes of the Low Incidence of Cervical Cancer in Western Asia

Authors:  Ghazi Alsbeih
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25

9.  Modelling risk assessment for cervical cancer in symptomatic Saudi women.

Authors:  Wedad Al-Madani; Anwar E Ahmed; Haitham Arabi; Sumaiah Al Khodairy; Nashmia Al Mutairi; Abdul Rahman Jazieh
Journal:  Saudi Med J       Date:  2019-05       Impact factor: 1.484

10.  Physician's knowledge and opinions on human papillomavirus vaccination: a cross-sectional study, Saudi Arabia.

Authors:  Nisreen M Anfinan
Journal:  BMC Health Serv Res       Date:  2019-12-12       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.